GEN Exclusives

More »

Corporate Profiles

More »
Sep 1, 2011 (Vol. 31, No. 15)

Chinese Genomics Firm Expands Operations

BGI Americas Provides Sales and Customer Support in North, South, and Central America

  • Click Image To Enlarge +
    BGI’s supercomputing centers store, process, and analyze the data generated by its next-generation sequencing technologies.

    When a deadly foodborne strain of Escherichia coli recently killed dozens of people in Europe, researchers at BGI (formerly Beijing Genomics Institute) teamed up with collaborators at the University Medical Centre Hamburg-Eppendorf to sequence the microbe's genome. They determined that the new infectious strain, called O104:H4, carries disease-causing genes from two other pathogenic E. coli and several antibiotic resistance genes, and it produces a Shiga-like toxin.

    BGI experts also developed, and made freely available, a PCR diagnostic detection protocol and synthesized primers that rapidly identify O104:H4 within two to three hours.

    BGI started in 1999 as part of the Human Genome Project; BGI Americas was founded in April 2010 as a commercial interface. BGI co-founders Huanming Yang, Ph.D., and Wang Jian, Ph.D., left the Chinese Academy of Sciences to build BGI, headquartered in Shenzhen, China. BGI contributed 1% of the Human Genome Project and was a core center for the International HapMap Consortium.

    About 3,000 genetic researchers, computer programmers, and bioinformaticians operate 137 Illumina HiSeq 2000 sequencers and 27 Life Technologies SOLiD sequencers, and analyze the output. These next-generation sequencers churn out 5 terabases per day, equivalent to 1,500 human genomes. The data-processing center contains 50,000 CPUs with 200 terabytes of RAM.

    The size of BGI guarantees a rapid turnaround and cost effectiveness, according to Dr. Yang. Due to the breadth of BGI's capabilities, “we offer a comprehensive set of services, including a full range of genomic sequencing (whole genome, de novo, target region, and exome), transcriptomics, epigenomics, metagenomics, and proteomics,” he adds.

    The bioinformatic experts at BGI not only provide significant data analysis but also invent new technologies such as SOAP (short oligonucleotide analysis package), a software system for analyzing next-generation sequence data.

    BGI is nominally nonprofit, and for-profit relationships set up by BGI Americas with pharmaceutical companies and other clients offset the nonprofit programs. Pharmaceutical firms, universities, and research institutes in the United States provide an important market for BGI. Currently, BGI serves 15 of the top 20 pharmaceutical companies.

    “Genomics is international and having a presence in the U.S. gives us closer proximity to nurture and build upon those valued relationships,” says Dr. Yang. Currently, 40 people work for BGI Americas and staff will be added as needed.

    BGI Americas focuses on sales and customer support teams and it is branching out to establish service laboratories. Among the first is a partnership with the University of California-Davis (UC Davis) to sequence genomes important in the areas of food security, human and animal health, and biodiversity and environmental health.

    Pharmaceutical companies that use BGI's services speed their discovery programs and avoid the costs of buying sequencing equipment and informatic services, Dr. Yang says. “We can help pharmaceutical companies identify drug targets, locate better biomarkers, enhance patient selection for clinical trials, and optimize bioproduction,” he adds. The next promising areas are personalized medicine and the clinical diagnostics market.

    BGI Americas offers fee-for-service capabilities in North, South, and Central America. Samples will be analyzed in Hong Kong, but the office in Cambridge can coordinate the shipping and paperwork. The returned report contains not only sequencing data but also annotation, mapping, analysis, or whatever the customer specifies. A similar facility in Copenhagen, Denmark, serves European clients.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?